Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by LEO Pharma
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Provides an Update on the Development Program for TMB-001 in Congenital Ichthyosis
August 21, 2024
From
LEO Pharma
Via
Business Wire
LEO Pharma Receives Positive CHMP Opinion of Anzupgo® (delgocitinib cream) for the Treatment of Adults with Moderate to Severe Chronic Hand Eczema (CHE)
July 26, 2024
From
LEO Pharma
Via
Business Wire
LEO Pharma Announces Publication of Chronic Hand Eczema Phase 3 Data in The Lancet
July 19, 2024
From
LEO Pharma
Via
Business Wire
LEO Pharma Announces Topline Results of Phase 3 Trial in China for Enstilar® (LEO 90100) Demonstrating Superiority in Adult Chinese Subjects With Stable Plaque Psoriasis
May 07, 2024
From
LEO Pharma
Via
Business Wire
Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology
May 03, 2024
From
LEO Pharma
Via
Business Wire
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
March 10, 2024
From
LEO Pharma
Via
Business Wire
LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas
March 06, 2024
From
LEO Pharma
Via
Business Wire
Annual Report 2023: LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA
February 29, 2024
From
LEO Pharma
Via
Business Wire
LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream With Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)
January 24, 2024
From
LEO Pharma
Via
Business Wire
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
January 23, 2024
From
LEO Pharma
Via
Business Wire
LEO Pharma Inc. Announces U.S. FDA approval of Adbry® (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years
December 15, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Announces Positive Outcome of DELTA 3 Open-Label Extension Trial of Delgocitinib Cream in the Treatment of Adults With Moderate to Severe Chronic Hand Eczema (CHE)
October 30, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023
October 13, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
October 13, 2023
From
LEO Pharma
Via
Business Wire
Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial
October 11, 2023
From
LEO Pharma
Via
Business Wire
Globally Known Professor and Dermatologist Joins LEO Pharma
October 09, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma delivers solid first half-year results and strengthens its capital structure
September 12, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma announces changes to its Global Leadership Team
August 28, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
August 21, 2023
From
LEO Pharma
Via
Business Wire
EMA Accepts LEO Pharma’s Marketing Authorization Application (MAA) for Delgocitinib Cream in Chronic Hand Eczema (CHE)
August 18, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting
March 18, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023
March 18, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Presents New Adbry™ (tralokinumab-ldrm) Data in Adolescent Population from ECZTRA 6 and ECZTEND Trials at AAD 2023 Annual Meeting
March 17, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Adds Internationally Recognized Dermatologist to Global Leadership Team
March 14, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
March 10, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 2 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE), Confirming the Positive Results of the Recent DELTA 1 Trial
February 10, 2023
From
LEO Pharma
Via
Business Wire
LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)
December 06, 2022
From
LEO Pharma
Via
Business Wire
LEO Pharma Launches AD Days Around the World Campaign to Raise Awareness of the Impact of Atopic Dermatitis Across Cultures
October 03, 2022
From
LEO Pharma
Via
Business Wire
LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis
September 29, 2022
From
LEO Pharma
Via
Business Wire
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis
September 19, 2022
From
LEO Pharma
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.